Member of the Association of American Physicians
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Primary hyperparathyroidism, Osteoporosis and Hyperparathyroidism. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Surgery. His research integrates issues of Calcimimetic and Cancellous bone in his study of Endocrinology.
He combines subjects such as Urology, Parathyroidectomy, Asymptomatic, Pathology and Femoral neck with his study of Primary hyperparathyroidism. His research investigates the connection with Osteoporosis and areas like MEDLINE which intersect with concerns in Hypoparathyroidism. His Hyperparathyroidism research is multidisciplinary, incorporating perspectives in Prospective cohort study and Calcium.
His main research concerns Internal medicine, Endocrinology, Osteoporosis, Primary hyperparathyroidism and Parathyroid hormone. His study in Internal medicine concentrates on Bone remodeling, Bone mineral, Bone density, Vitamin D and neurology and Calcium. In his study, Urology is inextricably linked to Femoral neck, which falls within the broad field of Bone mineral.
As part of his studies on Endocrinology, John P. Bilezikian often connects relevant subjects like Receptor. The study incorporates disciplines such as Anabolism, Bioinformatics and Intensive care medicine in addition to Osteoporosis. John P. Bilezikian has researched Primary hyperparathyroidism in several fields, including Parathyroidectomy, Hyperparathyroidism, Asymptomatic and Disease.
John P. Bilezikian mainly investigates Internal medicine, Endocrinology, Osteoporosis, Primary hyperparathyroidism and Parathyroid hormone. His studies deal with areas such as Gastroenterology and MEDLINE as well as Internal medicine. Within one scientific family, John P. Bilezikian focuses on topics pertaining to Placebo under Endocrinology, and may sometimes address concerns connected to Randomized controlled trial.
His Primary hyperparathyroidism research includes elements of Urology, Parathyroidectomy, Hyperparathyroidism, Asymptomatic and Disease. His research in Parathyroid hormone intersects with topics in Cancellous bone, Pathology, Endocrine system and Skeleton. The various areas that John P. Bilezikian examines in his Bone mineral study include Postmenopausal women and Femoral neck.
John P. Bilezikian spends much of his time researching Internal medicine, Endocrinology, Osteoporosis, Parathyroid hormone and Hypoparathyroidism. His biological study spans a wide range of topics, including Diabetes mellitus, Canagliflozin and Type 2 Diabetes Mellitus. The Endocrinology study combines topics in areas such as Placebo, Randomized controlled trial and MEDLINE.
His Osteoporosis research incorporates elements of Surgery, Physical therapy and Radiology. His Radiology study combines topics in areas such as Osteitis fibrosa cystica, Primary hyperparathyroidism and Bone disease. His Parathyroid hormone research is multidisciplinary, relying on both Parathyroid hormone receptor, Bone resorption and RANKL.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Primer on the metabolic bone diseases and disorders of mineral metabolism
John P. Bilezikian;Roger Bouillon;Thomas Clemens;Juliet Compston.
Rhode Island dental journal (2013)
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Maria Luisa Brandi;Robert F. Gagel;Alberto Angeli;John P. Bilezikian.
The Journal of Clinical Endocrinology and Metabolism (2001)
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.
Shonni J. Silverberg;Elizabeth Shane;Thomas P. Jacobs;Ethel Siris.
The New England Journal of Medicine (1999)
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.
John P. Bilezikian;Aliya A. Khan;John T. Potts.
The Journal of Clinical Endocrinology and Metabolism (2009)
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
Rajesh V. Thakker;Paul J. Newey;Gerard V. Walls;John Bilezikian.
The Journal of Clinical Endocrinology and Metabolism (2012)
Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency
Bilezikian Jp;Morishima A;Bell J;Grumbach Mm.
The New England Journal of Medicine (1998)
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.
Stephen F. Hodgson;Nelson B. Watts;John P. Bilezikian;Bart L. Clarke.
Endocrine Practice (2003)
Extrapulmonary manifestations of COVID-19.
Aakriti Gupta;Aakriti Gupta;Mahesh V. Madhavan;Kartik Sehgal;Kartik Sehgal;Nandini Nair.
Nature Medicine (2020)
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
David W. Dempster;David W. Dempster;Felicia Cosman;Felicia Cosman;Etah S. Kurland;Hua Zhou.
Journal of Bone and Mineral Research (2001)
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
D. M. Black;J. P. Bilezikian;K. E. Ensrud;S. L. Greenspan.
The New England Journal of Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: